Sentence: Early Prostate-Specific Antigen ( PSA ) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer .
Drug combination annotation:
[{'class': 'POS', 'spans': ['Abiraterone', 'Enzalutamide'], 'is_context_needed': True}]